Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000623 · ClinicalTrials.gov registry record
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
A clinical trial, sponsored by Carelon Research.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT00000623: Completed study, sponsored by Carelon Research.
NCT00000623 is a clinical trial that has completed, run by Carelon Research. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000623 has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
Interventions
- DRUG Decitabine
- DRUG Deferoxamine
- DRUG Deferiprone
- DRUG Sildenafil
- DRUG Arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2000-07 |
| Est. Completion | 2006-07 |
What the finished NCT00000623 record still lists
NCT00000623 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which Decitabine is the first listed.
NCT00000623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000623 about?
NCT00000623 is a clinical study titled "Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)". The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve inv...
What is the current status of trial NCT00000623?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2000-07. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00000623?
The interventions under investigation include: Decitabine (DRUG), Deferoxamine (DRUG), Deferiprone (DRUG), Sildenafil (DRUG), Arginine (DRUG).
Who is sponsoring clinical trial NCT00000623?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia